Galapagos N.V.

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

  • Registration date 15 oct 2015 - 07:30
  • Statutory name Galapagos N.V.
  • Title Galapagos advances triple combination therapy in cystic fibrosis
  • Comments - GLPG2665, a next-generation (C2) corrector, together with the other two components of the triple combination, show up to six-fold greater chloride transport than Orkambi1) in vitro - Triple combination therapy of C2 with GLPG2222 and GLPG1837 expected to address 80% of mutations in the CF population - Multiple series of C2 correctors identified, each with unique mode of action - GLPG2665 enters pre-clinical development and completes the first Galapagos-AbbVie triple combination therapy

Date last update: 19 September 2020

Share information

Share on: Share this